The immunogenicity and safety of GSK's recombinant hepatitis B vaccine in adults: a systematic review of 30 years of experience

• المؤلفون الرئيسيون: Caroline Van Den Ende (مؤلف), Cinzia Marano (مؤلف), Ayla Van Ahee (مؤلف), Eveline M. Bunge (مؤلف), Laurence De Moerlooze (مؤلف)
• التنسيق: كتاب
• منشور في: Taylor & Francis Group, 2017-08-01T00:00:00Z.
• الموضوعات: article
• الوصول للمادة أونلاين: Connect to this object online.

Introduction: Engerix B (GSK HepB, GSK, Belgium) was the first recombinant hepatitis B virus vaccine to be licensed, and marked its 30th anniversary in 2016. Vaccination of adult populations against HBV is usually implemented on a risk-based approach with varying degrees of success. Confirmation of...